Sentinan is a healthtech startup building the future of cardiac and pulmonary diagnostics through explainable AI and digital auscultation. Our solution combines FDA-approved stethoscope hardware with proprietary AI that detects and explains heart and lung abnormalities — helping clinicians detect conditions like valve disorders, heart failure, and pneumonia earlier and with greater confidence.
We are headquartered in Singapore and focused on Southeast Asia (SEA), where cardiovascular disease causes nearly 4 million deaths each year and many communities lack access to specialist diagnostics. Sentinan’s integrated hardware-software platform enables smarter frontline screening, augments telemedicine, and improves triage accuracy — from eldercare centers to hospital-at-home settings.
Our Product
🔹 Generation 1 Device: Powered by the Mintti Smartho-D2 (FDA-cleared), paired with our AI software.
🔹 Explainable AI: Built with NUS collaborators, our DiagramNet model provides clinician-friendly visual explanations, not just predictions.
🔹 Telehealth-Ready: Enables remote auscultation and AI triage through mobile and web platforms.
🔹 SaaS Model: Transitioning from hardware sales to a scalable subscription platform for clinics, hospitals, and telehealth partners.
Company Details
- Employees
- 4
- Founded
- -
- Address
- Singapore, Sg
- Industry
- Hospitals And Health Care
- NAICS
-
Health Care and Social AssistanceSocial Assistance
- Website
- http://www.sentinan.com
- Keywords
- Senserbot.
- HQ
- Singapore
Sentinan Questions
Sentinan's website is http://www.sentinan.com
Sentinan's LinkedIn profile is https://sg.linkedin.com/company/sentinan
Sentinan has
4 employees.
View email and phone details for 4
employees at Sentinan.
Sentinan's industry is
Hospitals and Health Care
Sentinan's top competitors are
Uthoppia House,
Miea Health,
Unfiltered,
Marymount Labs,
Senserbot,
M.i. Cloud Tech Pte Ltd,
Serentinel,
Quantumtx Pte Ltd,
Eyequila,
Soundeye.
Sentinan's categories are Hospitals and Health Care
Sentinan's founding year is 2025
